Celgene Corp. Sees Unusually High Options Volume (CELG)
Celgene Corp. (NASDAQ:CELG) was the recipient of unusually large options trading on Friday. Stock investors purchased 13,733 call options on the company, AnalystRatingsNetwork.com reports. This represents an increase of approximately 141% compared to the average volume of 5,707 call options.
CELG has been the subject of a number of recent research reports. Analysts at Leerink Swann raised their price target on shares of Celgene Corp. (NASDAQ:CELG) from $165.00 to $177.00 in a research note to investors on Wednesday, September 25th. They now have an “outperform” rating on the stock. Separately, analysts at TheStreet reiterated a “buy” rating on shares of Celgene Corp. (NASDAQ:CELG) in a research note to investors on Tuesday, September 24th. Finally, analysts at Goldman Sachs Group Inc. raised their price target on shares of Celgene Corp. (NASDAQ:CELG) from $113.00 to $129.00 in a research note to investors on Wednesday, September 18th. Six analysts have rated the stock with a hold rating and twenty-four have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $142.48.
Celgene Corp. (NASDAQ:CELG) traded up 3.05% during mid-day trading on Friday, hitting $157.27. 2,725,501 shares of the company’s stock traded hands. Celgene Corp. has a 1-year low of $71.23 and a 1-year high of $157.50. The stock’s 50-day moving average is $145.1 and its 200-day moving average is $129.6. The company has a market cap of $64.681 billion and a P/E ratio of 42.68.
Celgene Corp. (NASDAQ:CELG) last announced its earnings results on Thursday, July 25th. The company reported $1.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.44 by $0.08. The company had revenue of $1.56 billion for the quarter, compared to the consensus estimate of $1.54 billion. During the same quarter in the previous year, the company posted $1.22 earnings per share. The company’s revenue for the quarter was up 17.0% on a year-over-year basis. On average, analysts predict that Celgene Corp. will post $5.96 earnings per share for the current fiscal year.
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.